vs
CytomX Therapeutics, Inc.（CTMX）与ROCKWELL MEDICAL, INC.（RMTI）财务数据对比。点击上方公司名可切换其他公司
CytomX Therapeutics, Inc.的季度营收约是ROCKWELL MEDICAL, INC.的1.0倍（$18.7M vs $18.3M），CytomX Therapeutics, Inc.净利率更高（-0.8% vs -3.0%，领先2.2%），ROCKWELL MEDICAL, INC.同比增速更快（-25.6% vs -25.7%），ROCKWELL MEDICAL, INC.自由现金流更多（$2.2M vs $-15.8M），过去两年ROCKWELL MEDICAL, INC.的营收复合增速更高（-10.1% vs -15.9%）
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
罗克韦尔医疗成立于1996年，总部位于美国密歇根州威克瑟姆，是一家上市制药企业，核心业务聚焦于终末期肾病与慢性肾病相关治疗方案的研发与商业化推广。
CTMX vs RMTI — 直观对比
营收规模更大
CTMX
是对方的1.0倍
$18.3M
营收增速更快
RMTI
高出0.1%
-25.7%
净利率更高
CTMX
高出2.2%
-3.0%
自由现金流更多
RMTI
多$18.0M
$-15.8M
两年增速更快
RMTI
近两年复合增速
-15.9%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $18.3M |
| 净利润 | $-154.0K | $-554.0K |
| 毛利率 | — | 21.1% |
| 营业利润率 | -6.9% | -2.2% |
| 净利率 | -0.8% | -3.0% |
| 营收同比 | -25.7% | -25.6% |
| 净利润同比 | 97.6% | 26.7% |
| 每股收益（稀释后） | — | $-0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTMXRMTI
| Q4 25 | — | $18.3M | ||
| Q3 25 | — | $15.9M | ||
| Q2 25 | $18.7M | $16.1M | ||
| Q1 25 | $50.9M | $18.9M | ||
| Q4 24 | $38.1M | $24.7M | ||
| Q3 24 | $33.4M | $28.3M | ||
| Q2 24 | $25.1M | $25.8M | ||
| Q1 24 | $41.5M | $22.7M |
净利润CTMXRMTI
| Q4 25 | — | $-554.0K | ||
| Q3 25 | — | $-1.8M | ||
| Q2 25 | $-154.0K | $-1.5M | ||
| Q1 25 | $23.5M | $-1.5M | ||
| Q4 24 | $18.9M | $-756.0K | ||
| Q3 24 | $5.7M | $1.7M | ||
| Q2 24 | $-6.5M | $343.0K | ||
| Q1 24 | $13.8M | $-1.7M |
毛利率CTMXRMTI
| Q4 25 | — | 21.1% | ||
| Q3 25 | — | 14.3% | ||
| Q2 25 | — | 15.6% | ||
| Q1 25 | — | 16.1% | ||
| Q4 24 | — | 14.7% | ||
| Q3 24 | — | 22.0% | ||
| Q2 24 | — | 17.6% | ||
| Q1 24 | — | 13.5% |
营业利润率CTMXRMTI
| Q4 25 | — | -2.2% | ||
| Q3 25 | — | -9.9% | ||
| Q2 25 | -6.9% | -8.4% | ||
| Q1 25 | 44.4% | -7.2% | ||
| Q4 24 | 46.4% | -2.1% | ||
| Q3 24 | 12.3% | 6.8% | ||
| Q2 24 | -33.7% | 2.0% | ||
| Q1 24 | 28.1% | -5.8% |
净利率CTMXRMTI
| Q4 25 | — | -3.0% | ||
| Q3 25 | — | -11.0% | ||
| Q2 25 | -0.8% | -9.3% | ||
| Q1 25 | 46.2% | -8.0% | ||
| Q4 24 | 49.6% | -3.1% | ||
| Q3 24 | 17.2% | 5.9% | ||
| Q2 24 | -26.0% | 1.3% | ||
| Q1 24 | 33.3% | -7.6% |
每股收益（稀释后）CTMXRMTI
| Q4 25 | — | $-0.01 | ||
| Q3 25 | — | $-0.05 | ||
| Q2 25 | — | $-0.05 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | — | $-0.02 | ||
| Q3 24 | — | $0.04 | ||
| Q2 24 | — | $0.01 | ||
| Q1 24 | — | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.0M | $10.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $119.9M | $37.0M |
| 总资产 | $175.1M | $57.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTMXRMTI
| Q4 25 | — | $10.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | $49.0M | $12.5M | ||
| Q1 25 | $47.6M | $11.4M | ||
| Q4 24 | $38.1M | $15.7M | ||
| Q3 24 | $40.6M | $12.3M | ||
| Q2 24 | $43.2M | $11.9M | ||
| Q1 24 | $36.2M | $6.6M |
股东权益CTMXRMTI
| Q4 25 | — | $37.0M | ||
| Q3 25 | — | $37.0M | ||
| Q2 25 | $119.9M | $30.4M | ||
| Q1 25 | $25.0M | $31.5M | ||
| Q4 24 | $-456.0K | $32.6M | ||
| Q3 24 | $-23.5M | $29.1M | ||
| Q2 24 | $-31.2M | $23.5M | ||
| Q1 24 | $-31.7M | $20.6M |
总资产CTMXRMTI
| Q4 25 | — | $57.1M | ||
| Q3 25 | — | $57.5M | ||
| Q2 25 | $175.1M | $52.6M | ||
| Q1 25 | $98.5M | $54.0M | ||
| Q4 24 | $120.5M | $59.2M | ||
| Q3 24 | $139.0M | $57.1M | ||
| Q2 24 | $159.2M | $53.0M | ||
| Q1 24 | $184.7M | $50.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $2.3M |
| 自由现金流经营现金流 - 资本支出 | $-15.8M | $2.2M |
| 自由现金流率自由现金流/营收 | -84.6% | 12.0% |
| 资本支出强度资本支出/营收 | 0.1% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-77.7M | $-1.2M |
8季度趋势，按日历期对齐
经营现金流CTMXRMTI
| Q4 25 | — | $2.3M | ||
| Q3 25 | — | $-1.3M | ||
| Q2 25 | $-15.8M | $1.8M | ||
| Q1 25 | $-21.0M | $-3.5M | ||
| Q4 24 | $-19.9M | $865.0K | ||
| Q3 24 | $-20.7M | $4.3M | ||
| Q2 24 | $-19.5M | $1.4M | ||
| Q1 24 | $-26.0M | $-2.4M |
自由现金流CTMXRMTI
| Q4 25 | — | $2.2M | ||
| Q3 25 | — | $-1.5M | ||
| Q2 25 | $-15.8M | $1.7M | ||
| Q1 25 | $-21.2M | $-3.5M | ||
| Q4 24 | $-20.0M | $470.0K | ||
| Q3 24 | $-20.7M | $4.1M | ||
| Q2 24 | $-19.6M | $1.2M | ||
| Q1 24 | $-26.2M | $-2.5M |
自由现金流率CTMXRMTI
| Q4 25 | — | 12.0% | ||
| Q3 25 | — | -9.6% | ||
| Q2 25 | -84.6% | 10.5% | ||
| Q1 25 | -41.6% | -18.8% | ||
| Q4 24 | -52.5% | 1.9% | ||
| Q3 24 | -62.1% | 14.4% | ||
| Q2 24 | -78.2% | 4.5% | ||
| Q1 24 | -63.1% | -11.1% |
资本支出强度CTMXRMTI
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 1.4% | ||
| Q2 25 | 0.1% | 1.0% | ||
| Q1 25 | 0.2% | 0.3% | ||
| Q4 24 | 0.2% | 1.6% | ||
| Q3 24 | 0.1% | 0.7% | ||
| Q2 24 | 0.4% | 1.1% | ||
| Q1 24 | 0.3% | 0.6% |
现金转化率CTMXRMTI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | 2.57× | ||
| Q2 24 | — | 4.20× | ||
| Q1 24 | -1.89× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
RMTI
| US | $15.9M | 87% |
| Non Us | $2.4M | 13% |
